RGC · Regencell Bioscience Holdings Ltd
$5.49
-0.05 (-0.90%)
At close · Aug 26
Market Cap
$2.61B
Shares
494.49M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.54
Open$5.39
Day$5.17–5.55
52W close$4.78–52.88
Avg vol 30d206K
Short int990K · 0.2% float · 4.7d
Short vol39%
DataJun 2025–Aug 2026
Raw chart and full-history price indicators begin at the captured split on Jun 16, 2025; bars on opposite sides are not compared.
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−73%
below
Price vs 50-day avg
−18%
below
RSI (14)
42
neutral
MACD trend
Positive
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−7%
trailing
6-month return
−78%
trailing
YTD return
−74%
this year
Relative strength
−90%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $20 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.20% of float · ▲ +9.7% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
36 holders — near 3-yr high, broad support
Squeeze score
44
elevated · 0–100
Fundamentals
EPS growth
+17%
Y/Y
Free cash flow
$-3.3M
Balance sheet
$3.4M
net cash
Quant / Vol
risk profile
Volatility
146%
annualized · 1-yr
Max drawdown
−91%
past year
ATR
11.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−73%
Bearish
Price vs 50-day avg
−18%
Bearish
RSI (14)
42
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $20 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.20% of float · ▲ +9.7% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
36 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $6 · 2%
Range high $53
vs 200-day avg -73%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RGC
this stock
Regencell Bioscience Holdings Ltd
|
$2.61B | -73.6% | — | — | 0.2% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.25B | +17.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.94B | +3.4% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.77B | +0.7% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Jun 16, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RGC | +1.5% | -7.2% | -78.2% | -10.4% | -73.6% |
| SPY | -0.2% | +3.4% | +11.8% | +2.5% | +12.3% |
| vs SPY | +1.7% | -10.6% | -90.0% | -12.9% | -85.9% |